Abstract:The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million confirmed cases and 478,000 deaths (as of June 24th, 2020). The high intensive care unit (ICU) admission rate and mortality of COVID-19 is continuously posing a serious strain on the global health-care system. While most patients present with mild to moderate symptoms, some patients may develop life-threatening sepsis, respiratory failure, acute respiratory distress syndrome (ARDS) and multiple organ failure. However, current antiviral and supportive therapies are not sufficient to prevent or treat the above complications especially in severely ill COVID-19 patients [1]. Thus, it is urgent to find the underlying mechanism dominating such life-threatening complications. It is well recognized that lung damage and multi-organ failure in this subgroup of patients arise due to overwhelming systemic hyper-inflammation. Therefore, promising anti-inflammatory candidate agents targeting diverse mechanisms related to cytokine storm will be therapeutically relevant (Fig. 1 ). Open in a separate window Fig. 1 Potential therapies of COVID-19 by targeting inflammation and cytokine storm. SARS-CoV-2 enters and infects cells by binding to TMPRSS2 and ACE2, subsequently releases virus RNA, one of the PAMPs, and recruits dendritic cells, macrophages and neutrophils. The released type I interferon and pro-inflammatory cytokines and chemokines induce the innate immune response while adaptive immune response is ignited by activating T and B lymphocytes to defend against the virus. Meanwhile, intact viruses or the components can directly activate the NLRP3 inflammasome, leading to IL-1β secretion. In most infections, moderate immune response and antiviral response are capable to combat the infection. Nevertheless, in individuals with immunological dysfunction, persistent hyper-inflammation triggers a cytokine storm, leading to the lung injury and ARDS or eventually swept through the whole body, causing MODS. During the pathological progression, the inhibition of NRLP3, JAK1/2, IL-6, BRD4 and the infusion of IVIG may be beneficial in suppressing the overwhelming inflammation and arrest or reverse the COVID-19 disease. Abbreviations: ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory distress syndrome; IVIG, intravenous immunoglobulin; MODS, multiple organ dysfunction syndrome; NLRP3, Nod-like receptor protein 3; PAMP, pathogen-associated molecular pattern; TMPRSS2, transmembrane serine protease 2.

Drug Repurposing of Anti-Infective Clinical Drugs: Discovery of Two Potential Anti-Cytokine Storm Agents

Therapeutic Targeting of Interleukin-6 for the Treatment of COVID-19.

Transcriptomic Signatures and Repurposing Drugs for COVID-19 Patients: Findings of Bioinformatics Analyses

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

Drug Repurposing Using Gene Co-Expression and Module Preservation Analysis in Acute Respiratory Distress Syndrome (ARDS), Systemic Inflammatory Response Syndrome (SIRS), Sepsis, and COVID-19

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Targeting Inflammation and Cytokine Storm in COVID-19

Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model

Are Anti-Inflammatory Drugs Effective In Patients With COVID-19 Cytokine Storm: A Review

Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19)

Repurposing of Anti-Cancer Drugs Against Moderate and Severe COVID Infection: A Network-Based Systems Biological Approach

Glycyrrhetinic acid: A potential drug for the treatment of COVID-19 cytokine storm

Inspiration for COVID-19 Treatment: Network Analysis and Experimental Validation of Baicalin for Cytokine Storm

Potential Clinical Drugs As Covalent Inhibitors of the Priming Proteases of the Spike Protein of SARS-CoV-2

Immunotherapy Summary for Cytokine Storm in COVID-19

Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics

An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Drug Repurposing of Itraconazole and Estradiol Benzoate Against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion

The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Prediction of repurposed drugs for treating lung injury in COVID-19